Retinal cases & brief reports · 2025
NONSURGICAL CLOSURE OF FULL-THICKNESS MACULAR HOLE UNDER TOPICAL THERAPY IN TWO EYES WITH PATHOLOGIC MYOPIA.
СтатьяКлинический случайНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Miyata Mana, Ueta Takashi, Aoki Shuichiro, Kitamoto Kohdai, Azuma Keiko, Obata Ryo
Аннотация
BACKGROUND/PURPOSE: Nonsurgical closure of a full-thickness macular hole (FTMH) with eye drops has recently been reported, but there are few similar reports on cases with pathologic myopia.
METHODS: Case report.
RESULTS: (Case 1) The right eye of a 75-year-old female patient with an axial length of 28.83 mm had undergone anti-vascular endothelial growth factor treatment for choroidal neovascularization presented with FTMH. Topical betamethasone, bromfenac, and brinzolamide treatments were started, and the FTMH was closed with visual improvement (20/32 to 20/20) after 5 weeks. (Case 2) In the right eye of a 55-year-old male patient with an axial length of 30.81 mm and lacquer cracks, subretinal hyperreflective material and FTMH developed. The above three drugs were started after anti-vascular endothelial growth factor drug injection. After 16 weeks, the FTMH was closed with visual improvement (20/63 to 20/20).
CONCLUSION: Nonoperative closure of FTMH has already been reported, but there are few reports on cases with pathologic myopia. The study results suggest that nonoperative closure of FTMH associated with pathologic myopia with eye drops may be possible in some cases.
METHODS: Case report.
RESULTS: (Case 1) The right eye of a 75-year-old female patient with an axial length of 28.83 mm had undergone anti-vascular endothelial growth factor treatment for choroidal neovascularization presented with FTMH. Topical betamethasone, bromfenac, and brinzolamide treatments were started, and the FTMH was closed with visual improvement (20/32 to 20/20) after 5 weeks. (Case 2) In the right eye of a 55-year-old male patient with an axial length of 30.81 mm and lacquer cracks, subretinal hyperreflective material and FTMH developed. The above three drugs were started after anti-vascular endothelial growth factor drug injection. After 16 weeks, the FTMH was closed with visual improvement (20/63 to 20/20).
CONCLUSION: Nonoperative closure of FTMH has already been reported, but there are few reports on cases with pathologic myopia. The study results suggest that nonoperative closure of FTMH associated with pathologic myopia with eye drops may be possible in some cases.
Предметные рубрики MeSH
HumansRetinal PerforationsMaleMiddle AgedMyopia, DegenerativeAgedFemaleOphthalmic SolutionsBenzophenonesTomography, Optical CoherenceBromobenzenesBetamethasoneThiazinesAdministration, TopicalSulfonamidesVisual AcuityGlucocorticoidsAngiogenesis InhibitorsCarbonic Anhydrase InhibitorsAnti-Inflammatory Agents, Non-Steroidal